Abstract Background: Phenylephrine eye drops and intravenous (IV) atropine are commonly used in ophthalmic surgery to maintain pupil dilation and counteract the oculocardiac reflex, respectively. However, their combination can lead to severe cardiovascular complications. This study investigates the synergistic effects of these drugs on blood pressure and heart rate in pediatric patients and a rat model. Methods: Clinical data from 13 pediatric patients (ages 7–14) undergoing intraocular surgery were analyzed. Additionally, 72 Sprague-Dawley rats were studied to evaluate the impact of administration sequence, time intervals, and the efficacy of reversal agents. Findings: In pediatric patients, the drug combination caused a significant hypertensive emergency, with systolic blood pressure (SBP) increasing by over 20% for up to 25 minutes. In rats, the cardiovascular spike was dependent on the time interval between drug administrations rather than the sequence. Neostigmine was found to effectively reverse the hypertensive effects. Interpretation: The combination of phenylephrine and atropine should be used with extreme caution, maintaining at least a 10-minute buffer between administrations, with neostigmine available for emergency reversal.
Introduction
In ophthalmic surgery, clinicians often manage a delicate pharmacological balance. Phenylephrine eye drops are the standard for maintaining mydriasis (pupil dilation), while intravenous (IV) atropine is frequently administered to counteract the oculocardiac reflex (OCR)—a sudden, dangerous drop in heart rate caused by physical manipulation of the eye.
While both drugs are considered safe when used individually, clinical observations have suggested that their combined use can trigger a synergistic "hypertension emergency." This study seeks to quantify these risks, define the window of maximum danger, and identify effective pharmacological interventions to reverse adverse effects.
Methods
The researchers employed a two-pronged investigative approach:
- Clinical Observation: A retrospective study was conducted on 13 pediatric patients (ages 7–14, average age 10.7) at the Zhongshan Ophthalmic Center. These patients received 5% phenylephrine eye drops and subsequently required IV atropine during surgery due to OCR. Blood pressure (BP) and heart rate (HR) were monitored for 30 minutes following atropine administration.
- Animal Study: To isolate variables, 72 Sprague-Dawley rats were divided into groups to test the effects of administration sequence (phenylephrine before atropine vs. vice versa) and time intervals (5, 10, or 15 minutes). The study also evaluated the efficacy of neostigmine (a cholinesterase inhibitor) and esmolol (a beta-blocker) as reversal agents for the resulting cardiovascular spikes.
Key Results
In the clinical cohort, the administration of IV atropine following phenylephrine eye drops led to a rapid and severe increase in cardiovascular metrics. Peak heart rate occurred 15 minutes post-atropine, while systolic blood pressure (SBP) surged from a baseline of 103.15 mmHg to 162.15 mmHg at the 10-minute mark. This hypertensive state, defined as a >20% increase from baseline, persisted for approximately 20 to 25 minutes.
The rat model revealed that the severity of the cardiovascular spike is dictated by the time interval between the two drugs rather than the sequence of administration. Spikes in BP and HR were significantly blunted when the drugs were administered 10 to 15 minutes apart, suggesting that the danger zone coincides with the peak plasma concentration of phenylephrine (typically 10–20 minutes post-instillation).
Regarding reversal, neostigmine was significantly more effective than esmolol at reducing the blood pressure surge. While esmolol is traditionally used for heart rate control, neostigmine successfully decreased both SBP and DBP (p < 0.001) compared to saline controls in this specific drug-drug interaction model.
Discussion and Conclusion
This study identifies a critical safety window for ophthalmic surgeons: the 10-minute period following phenylephrine instillation is a high-risk zone for introducing IV atropine. The resulting hypertensive emergency can risk target organ damage, particularly in patients with underlying cardio-cerebrovascular conditions.
While the clinical portion of the study was limited by a small sample size (n=13) and a predominantly male demographic, the animal data provides a clear pharmacological basis for the observed effects. The authors recommend that surgeons avoid the combination if possible. If both drugs are necessary, a minimum 10-minute buffer should be maintained, and neostigmine should be kept on hand as a preferred rescue agent to manage sudden hypertensive spikes.
Summary updated